https://www.live-feeds.com/feed/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technologyContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technologyhttps://www.live-feeds.com/feed/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technology#u17192Mon, 29 Jun 2026 10:47:20 +0000An FDA advisory committee voted 9-0 on June 18 to recommend mFlusiva for adults aged 50 and older. Phase 3 data indicated the vaccine is about 27% more effective than standard flu shots. Moderna aims for approval before the fall and winter seasons.What's confirmed:FDA advisers voted 9-0 on June 18 to back Moderna's mRNA flu vaccine mFlusiva.The recommendation covers adults aged 50 and older.Phase 3 data showed mFlusiva is about 27% more effective than a standard flu vaccine.Still unconfirmed:Approval for adults 65 and older may depend on a specific condition.The vaccine may be recommended https://www.live-feeds.com/feed/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technologyhttps://www.live-feeds.com/feed/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technology#u12415Thu, 25 Jun 2026 06:11:47 +0000An FDA advisory committee voted to recommend mFlusiva for adults aged 50 and older. The panel found the vaccine's benefits outweigh its risks. Moderna is seeking approval before the fall and winter flu seasons.What's confirmed:The FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 twice on June 18 to recommend mFlusiva.The vaccine is intended for adults aged 50 and older.Moderna is seeking approval for the shot before the fall and winter seasons.The FDA is evaluating the product known as mRNA-1010 or mFlusiva.Still unconfirmed:Faster production may improve th https://www.live-feeds.com/feed/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technologyhttps://www.live-feeds.com/feed/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technology#u8474Mon, 22 Jun 2026 14:45:48 +0000Federal health advisers have recommended the U.S. market approval of mFlusiva. This shot is the first flu vaccine to utilize mRNA technology. The FDA is currently evaluating the product from Moderna.What's confirmed:Federal health advisers recommended approval of the first mRNA flu vaccine on Thursday.The FDA is evaluating Moderna's new shot called mFlusiva. https://www.live-feeds.com/feed/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technologyhttps://www.live-feeds.com/feed/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technology#u6463Sat, 20 Jun 2026 21:16:23 +0000Federal health advisers recommended on Thursday that a new flu vaccine be approved for the U.S. market. The shot uses mRNA technology similar to that used during the pandemic. This is the first flu vaccine developed with this specific technology.What's confirmed:Federal health advisers recommended approval of a new flu vaccine on Thursday.The vaccine is the first of its kind to use mRNA technology.The mRNA technology used in this vaccine was key to ending the pandemic. https://www.live-feeds.com/feed/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technologyhttps://www.live-feeds.com/feed/fda-panel-backs-first-of-its-kind-flu-vaccine-using-mrna-technology#u4821Fri, 19 Jun 2026 17:32:40 +0000Federal health advisers on Thursday recommended the approval of Moderna's mRNA-based flu vaccine. The shot is intended for adults aged 50 and older. This marks the first flu vaccine developed using mRNA technology.What's confirmed:A federal advisory panel recommended approval of Moderna's mRNA flu vaccine on Thursday.The vaccine is intended for adults 50 and older.All nine committee members voted unanimously to recommend the vaccine.The vaccine uses the same mRNA technology used during the COVID-19 pandemic.Still unconfirmed:The vaccine is named MFLUSIVA.Phase 3 trials showed 26.6% R